Mild intraoperative hypothermia is common. We therefore studied the effects of mild hypothermia on propofol pharmacokinetics, hepatic blood flow, and atracurium duration of action in healthy volunteers. Six young volunteers were studied on two randomly assigned days, at either 34°C or 37°C. Anesthesia was induced with thiopental, 3 mg/kg, and maintained with 70% N,O and 0.6% isoflurane. Core hypothermia was induced by conductive and convective cooling. On the other study day, normothermia was maintained by a Bair Hugger@ (Augustine Medical, Inc., Eden Prairie, MN) forced-air warmer. Propofol, 1 mg/kg lean body mass (LBM), then was given, followed by a 4-h infusion at 5 mg * kg-' * h-i. After 2 h, atracurium 0.5 mg/kg was administered as an intravenous bolus. Indocyanine green was administered for estimation of hepatic blood flow. Arterial blood was assayed for propofol and indocyanine green concentration. Pharmacokinetic analysis was performed using NON-MEM. Results are reported as means ? SEM. Propofol blood concentrations averaged -28% more at 34°C than at 37°C (P < 0.05). Hepatic blood flow decreased 23% +-11% in normothermic volunteers during the propofol infusion, and 33% t 11% in hypothermic volunteers (P = not significant). A three-compartment mamillary model fitted the data best. Inclusion of hepatic blood flow change from the prepropofol baseline as a covariate for total body clearance significantly improved the fit. The intercompartmental clearances were decreased in the presence of hypothermia. Core hypothermia prolonged the time to recovery of the first twitch in the train-of-four to 10% of its control value (Tl = 10%) after atracurium administration by -60% (P < 0.05), from 44 + 4 min to 68 ? 7 min. In contrast, Tl = 25%-75% remained unchanged. We conclude that 3°C of core hypothermia increased propofol blood concentrations and prolonged atracurium duration of action. Hepatic blood flow was decreased during propofol administration, and this change was a significant predictor of propofol clearance, indicating that the effect of propofol on hepatic blood flow impairs the clearance of propofol itself.
Mild intraoperative hypothermia is common. We therefore studied the effects of mild hypothermia on propofol pharmacokinetics, hepatic blood flow, and atracurium duration of action in healthy volunteers. Six young volunteers were studied on two randomly assigned days, at either 34°C or 37°C. Anesthesia was induced with thiopental, 3 mg/kg, and maintained with 70% N,O and 0.6% isoflurane. Core hypothermia was induced by conductive and convective cooling. On the other study day, normothermia was maintained by a Bair Hugger@ (Augustine Medical, Inc., Eden Prairie, MN) forced-air warmer. Propofol, 1 mg/kg lean body mass (LBM), then was given, followed by a 4-h infusion at 5 mg * kg-' * h-i. After 2 h, atracurium 0.5 mg/kg was administered as an intravenous bolus. Indocyanine green was administered for estimation of hepatic blood flow. Arterial blood was assayed for propofol and indocyanine green concentration. Pharmacokinetic analysis was performed using NON-MEM. Results are reported as means ? SEM. Propofol blood concentrations averaged -28% more at 34°C than at 37°C (P < 0.05). Hepatic blood flow decreased 23% +-11% in normothermic volunteers during the propofol infusion, and 33% t 11% in hypothermic volunteers (P = not significant). A three-compartment mamillary model fitted the data best. Inclusion of hepatic blood flow change from the prepropofol baseline as a covariate for total body clearance significantly improved the fit. The intercompartmental clearances were decreased in the presence of hypothermia. Core hypothermia prolonged the time to recovery of the first twitch in the train-of-four to 10% of its control value (Tl = 10%) after atracurium administration by -60% (P < 0.05), from 44 + 4 min to 68 ? 7 min. In contrast, Tl = 25%-75% remained unchanged. We conclude that 3°C of core hypothermia increased propofol blood concentrations and prolonged atracurium duration of action. Hepatic blood flow was decreased during propofol administration, and this change was a significant predictor of propofol clearance, indicating that the effect of propofol on hepatic blood flow impairs the clearance of propofol itself. (Anesth Analg 1995; 80:1007-14) A lthough mild intraoperative hypothermia is common (l), the effects of mild hypothermia on anesthetic drug pharmacology are not well known. The volatile anesthetics are well defined, their potency increasing linearly as temperature decreases (=5%/"C) (2). Few studies have investigated the effects of mild hypothermia on intravenous drugs (3-6), and the pharmacokinetics of propofol during mild hypothermia remain unknown. In normothermic patients, propofol is rapidly and extensively redistributed, and has high clearance (7-9). Presumably, like other drugs with high extraction, propofol clearance is dependent on hepatic blood flow. If hypothermia significantly decreases hepatic blood flow (10) or alters volumes of distribution or clearance of propofol as it does with other drugs (3-6), higher propofol blood concentrations should result.
Mild hypothermia prolongs the duration of action of the muscle relaxants d-tubocurarine (-32°C) (11) and vecuronium (34.5"C) (12). Atracurium has not been studied during mild hypothermia, even though its unique metabolism (13) may mean that it is differently affected by hypothermia than either d-tubocurarine or vecuronium. We therefore studied the effects of mild hypothermia on atracurium duration of action, and on propofol pharmacokinetics and hepatic blood flow, in healthy volunteers. ANALG 1995; 80:1007-14 
Methods
With approval from the Committee on Human Research at the University of California, San Francisco, we studied two women and four men (aged 25 ? 1 yr (mean + SEM), height 174 5 2 cm, total body mass (TBM) 68 + 3 kg, lean body mass (LBM) 53 ? 2 kg, and body fat 21% -+ 2%), taking no medications. Women were studied during the first 10 days of their menstrual cycles. Each volunteer was studied on two occasions, separated by more than a week. Core hypothermia was induced on one day, and normothermia maintained on the other, the order randomly assigned. The LBM of each volunteer was determined from height (cm) and TBM (kg) using a formula (14) adapted to gender: females, LBM = (1.07. TBM) -1148 * (TBM/height)*l; males, LBM = (1.10 * TBM) -1128 * (TBM/height)*l. Lactated Ringer's solution was infused at 120 mL/h into a forearm vein of the nondominant arm and routine anesthesia monitors were applied. An integrated, computerized anesthesia machine (Modulus@ CD; Ohmeda, Inc., Madison, WI) was used to monitor standard anesthetic variables, including oscillometric blood pressure, heart rate, and oxygen saturation. End-tidal isoflurane and nitrous oxide (N,O) concentrations were quantified using a calibrated end-tidal gas analyzer (Datex Medical Instrumentation, Tewksbury, MA). Anesthetic data were recorded directly using automatic record-keeping software (IdaCareTM; Hermes System, Inc., Belgium).
Anesthesia was induced with thiopental, 3 mg/kg, followed by 70% N,O in oxygen and isoflurane (up to 5% inspired concentration), administered via a circle system. The trachea was intubated without the assistance of muscle relaxants, and the lungs were ventilated mechanically to maintain an end-tidal carbon dioxide partial pressure at 34-36 mm Hg. Anesthesia was maintained with 70% N,O in oxygen and 0.6% end-tidal isoflurane throughout the study, to prevent thermoregulatory vasoconstriction and to allow cooling (15).
On one study day, core hypothermia was induced via leg cooling, by gradually reducing the temperature of a circulating water mattress underneath the legs to 10°C (Blanketrol II, Maxi-Therm blanket No. 276; Cincinnati Sub-Zero, Cincinnati, OH). In addition, the legs were exposed and cooled with a fan. Active cooling was discontinued when core temperature reached 34.6"C; thereafter, cooling was passive. The target temperature of 34.O"C was maintained using a Bair Hugger@ forced-air warmer (Model 300 cover, Model 200 blower; Augustine Medical, Inc., Eden Prairie, MN). On the other study day, core temperature was maintained at 37.O"C using the Bair Hugger@.
Once target temperatures were obtained and 3 h had elapsed, a bolus of propofol (Stuart Pharmaceuticals, Inc., Wilmington, DE), 1 mg/kg LBM, was g iven, followed by an infusion at 5 mg * kg LBM-' * h-. The infusion was continued for 4 h. Two hours after starting the infusion, a single bolus of atracurium, 0.5 mg/kg (Burroughs Wellcome Co., Research Triangle Park, NC), was administered over 30 s. To estimate hepatic blood flow, a I-mg bolus of indocyanine green (Pulsion; Medizintechnik KG, Munich, Germany) was followed by an infusion of 12 mg/h starting 20 min prior to propofol administration and continuing until the end of the first hour. Subsequently, a similar bolus and infusion of indocyanine green was given in the last 20 min of each hour.
The study ended after 4 h of propofol infusion or recovery of neuromuscular function, whichever occurred later. Neostigmine, 35 pg/kg, and glycopyrrolate, 10 pg/kg, were administered, and after reestablishment of spontaneous ventilation, anesthesia was discontinued and the trachea extubated. Control values for arterial blood pressure, heart rate, oxygen saturation, and skin temperatures were recorded before induction of anesthesia.
Core temperature was measured before induction of anesthesia via the tympanic membrane and thereafter in the distal esophagus. Thenar skin temperature was measured on the dominant arm using self-adhesive probes. After induction of anesthesia, adductor pollicis muscle temperature in the dominant hand was measured using a 22-g, 18-mm needle thermocouple inserted directly into the muscle, 1 cm distal to the metacarpophalangeal joint (16). The dominant arm was shielded from heating and cooling devices. Forearm minus fingertip skin-temperature gradients (17) were measured on the dominant arm. Significant peripheral vasoconstriction was identified by a gradient exceeding 4°C. Ambient temperature was measured and maintained between 22 and 24°C. All temperatures were measured using Mon-a-Therm@ probes (Mallinckrodt Anesthesia Products, Inc.). Temperature data were recorded at 15-min intervals by a program written using LabVIEW@ graphical signal processing software (National Instruments, Inc., Austin, TX). Neuromuscular block was assessed in the dominant arm. Supramaximal, square-wave impulses of 0.2-ms duration in a train-of-four sequence (2 Hz) were delivered via cutaneous electrode pads over the ulnar nerve at the wrist using a Digistim II nerve stimulator (Neurotechnology, Inc., Houston, TX). Train-of-four stimuli were repeated at 15-s intervals, and the evoked mechanical response of the adductor pollicis muscle was quantified by a force-displacement transducer (Gould Statham, UTC3). Twitch tension was allowed to stabilize for 15 min, and control measurements were recorded immediately before atracurium administration. The times for recovery of the first twitch (Tl) in the train-of-four to 10% of its control height (Tl = lo%,>, and for recovery from 25% to 75% twitch height (Tl = 25%-75%) were measured.
Blood was sampled from a radial arterial catheter for propofol assay after commencement of the propofol infusion at 0,2, 4, 6, 8, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 210 , and 240 min. Samples were collected in heparinized tubes and stored at 4°C for up to 10 wk. Propofol blood concentrations decrease less than 0.2%/wk at 4°C. They were subsequently analyzed using a high-performance liquid chromatography assay, modified from the method of Plummer (18). This assay is linear to at least 20 mg/L, has a detection limit of 0.025 mg/L, and a coefficient of variation of 4.1% at 2 mg/L.
Arterial blood samples for indocyanine green assay were taken at 16,18, and 20 min of each dye infusion period, collected in heparinized tubes, and subsequently centrifuged.
The resulting supernatant was collected and stored at -20°C until analysis. There is no detectable degradation of samples frozen for periods of up to 3 mo. The indocyanine green assay was a modification of the method of Soons et al. (19) . This method uses diazepam as an internal standard, detection by ultraviolet absorbance at 800 nm, and a mobile phase of 54.8:42.3:3.8 50 mM KHJ'O, (pH 6.0):acetonitrile:methanol on a Waters Novapak C,, column. The method is linear to at least 20 mg/L, with a coefficient of variation of 2.6% at 2 mg/L, and a detection limit of 0.05 mg/L.
The NONMEM nonlinear regression program (version 4, level 1.0) (20) was used to derive pharmacokinetic variables for propofol, to determine whether any variable was related to estimated hepatic blood flow change and to estimate the influence of hypothermia. A modified stepwise approach analogous to multiple stepwise linear regression was used to determine which factors to include in the model. To examine the influence of an individual factor on the model, the following criteria were considered: the difference in -2 log likelihood (the objective function for NON-MEM, which is approximately J$ distributed), the SE of the variable estimates, plots of the residuals, and the residual intraindividual variability which corresponds to unexplained variability.
In view of the asymptotic nature of the 2 approximation, a conservative probability value (P < 0.005), equivalent to a minimum log-likelihood difference of 7.8, was chosen as the minimum improvement in objective function for a factor to be retained in the model (21).
One-, two-, and three-compartment models with elimination from the central compartment (mammillary models) were expressed in terms of total body clearance, intercompartmental clearances and compartment volumes. The logarithms of each of the pharmacokinetic variables were assumed to be normally distributed (22) . To express this in the nonlinear regression model, log-additive random (normally distributed) interindividual variation was assumed with a similar model used for intraindividual variability (22). In view of the small sample size and the large number of observations per subject, paired post-hoc individual estimates of each of the pharmacokinetic variables were used to discern the effects of hypothermia on propofol pharmacokinetics rather than the more usual population approach with NONMEM. Indocyanine green infusion rates and plasma concentrations were used to estimate hepatic blood flow (19). This method assumes that the indocyanine green intrinsic clearance remains constant during the study: where 0.7 is the assumed extraction ratio of indocyanine green. Consequently, hepatic blood flow during propofol, HBF,,,, (mL/min), was (24) (Eq. 4)
Repeated-measures analysis of variance was used to determine the effect of core temperature and elapsed time on propofol concentration and hepatic blood flow. Student's t-test, with Bonferroni correction for multiple comparisons, was used on pooled hypothermic and normothermic data to assess the effect of propofol on hepatic blood flow. Paired Student's ttests, with Bonferroni correction, were used to determine the effect of temperature on each of the pharmacokinetic variables of propofol.
Esophageal, adductor pollicis muscle, and thenar skin temperatures at the time of atracurium administration, when Tl = lo%, Tl = 25%, and Tl = 75% were compared using analysis of variance. Means were compared to values at the time of atracurium HYPOTHERMIA, PROPOFOL, AND ATRACURIUh4 ANALG 1995; 80:1007-14 Data presented as mean (95% confidence limits). TBC = total bodv clearance; HBF = heuatic blood flow; HBF,,. = prepropofol HBF; ICC = intercompartmental clearance; VD = volume of distribution. * P < 0.005 comiared with 37°C; ** P < 0.05 compared with r?C. _ -' administration with Dunnett's t-test. Durations to Tl = 10% and Tl = 25%-75% were compared using two-tailed, paired t-tests.
All results are presented as means ? SEM, unless specified otherwise; P < 0.05 was considered statistically significant.
Results
Each study lasted 7 h and no adverse effects were noted. Tympanic membrane temperatures before induction of anesthesia were 36.6 + O.l"C. Core hypothermia (34°C) was attained 142 +-9 min after induction of anesthesia. Core temperature returned to 37°C in the normothermic group 104 ? 7 min after induction. During the remainder of the study, esophageal temperatures were maintained at 34.02 + O.Ol"C and 37.02 + O.Ol"C, respectively. Peripheral vasoconstriction did not occur in any volunteer.
Propofol blood concentrations averaged 28% more at 34°C than at 37°C (P = 0.05). Hypothermic volunteers had propofol concentrations -1.35 pg/mL more than normothermic subjects at 2 min (3.34 + 1.62 pg/mL and 1.99 2 1.30 pg/mL, respectively) but, after 6 min, concentrations were only 0.35 + 0.06 pg/mL more. The effect of temperature on propofol concentrations was not constant over time (P = 0.006). A three-compartment mammillary model fit the data significantly better than one-or two-compartment models (P < 0.001 hypothermic and normothermic groups). Including the individual estimates of the change in estimated hepatic blood flow from the prepropofol baseline as a covariate for total body clearance also significantly improved the fit of the model to the data (P < 0.005). However, no association was demonstrated between hepatic blood flow changes and any other pharmacokinetic variable except clearance. The only pharmacokinetic variables having a significant association with hypothermia were the shallow and deep intercompartmental clearances, which were both decreased in the presence of hypothermia (P < 0.005 shallow, P < 0.05 deep) ( Table 1) . As the volunteers were very demographically homogeneous, no association was demonstrated between weight, age, or sex, and any of the pharmacokinetic variables. Figure 1 shows the observed propofol concentrations along with the predictions from the final model, with the effects of hepatic blood flow change and hypothermia included.
Estimated hepatic blood flow decreased 23% ? 11% in normothermic volunteers during the propofol infusion, and 33% + 11% in hypothermic volunteers (P = not significant between temperatures) (Fig. 2) . There was no significant change in hepatic blood flow produced by hypothermia in the absence of propofol, or after atracurium administration.
Induction of N,O/isoflurane anesthesia decreased systolic arterial blood pressure -20% compared to control values. In the 20 min after propofol administration, the pressure decreased an additional 5% when the volunteers were normothermic (P = not significant) and an additional 10% when they were hypothermic (P < 0.05), but the difference between the groups was not significant. Only at 120 min after commencement of the propofol infusion did systolic arterial blood pressure differ between the hypothermic and normothermic groups (Fig. 2) .
Core hypothermia significantly prolonged the time from injection of atracurium to recovery of Tl to 10% of its control height from 44 & 4 min to 68 + 7 min (-60% increase; P = 0.004). In contrast, the time for Tl to recover 25%-75% remained unchanged (20 + 4 and 23 2 5 min, respectively; P = 0.14) (Fig. 3) . Adductor pollicis muscle and thenar skin temperatures were measured in five of the six volunteers. Esophageal, adductor pollicis muscle, and thenar skin temperatures were unchanged from the time of atracurium administration to recovery of Tl = 75%. Adductor pollicis muscle temperatures were -0.4"C less than esophageal temperatures on both study days. Thenar skin temperatures were 1.3 + 0.04"C and 1.5 ? 0.04"C less than esophageal temperatures on the hypothermic and normothermic days, respectively.
Discussion
Mild hypothermia was associated with larger propofol blood concentrations at all times, but the greatest difference was observed during the first 5 min of drug administration. Greater peak propofol concentrations in the hypothermic group at this time probably reflected the early impact of decreased intercompartmental clearance, as there was no difference in central volumes of distribution between the two groups and arterial blood pressures decreased similarly. Propofol concentrations were persistently greater in hypothermic volunteers, reflecting the ongoing impact of propofol redistribution during the infusion.
Other pharmacokinetic variables were similar in the hypothermic and normothermic groups. The volumes of distribution presented here confirm previous reports in normothermic subjects that propofol is redistributed extensively after single doses (25, 26) and infusions (8,9). However, our estimate of total body clearance is less than previously reported, either after single doses or infusions. All data used for pharmacokinetic estimations in our study were obtained during anesthesia, whereas previous values were calculated from extended blood collection periods after termination of anesthesia. Propofol concentrations thus were at least one order of magnitude less in previous reports, which primarily used elimination phase data, rather than within-infusion data. Decreased hepatic blood flow induced by anesthetic blood concentrations of propofol, which in turn alters propofol total body clearance, implies strongly that the pharmacokinetits of propofol probably are not comparable in the anesthetized and awake states. In addition, the physiologic changes after surgery (27) make it even more difficult for previous pharmacokinetic studies based on extended postanesthetic blood collection periods to accurately predict propofol pharmacokinetics during infusion at anesthetic blood concentrations.
Alternatively, our total body clearance estimate may be biased by the short sampling period. Ethical considerations limited the study duration to 7 h, and we did not obtain samples after the termination of anesthesia, because core temperature was not constant, However, a short sampling period would be expected to produce spuriously high estimates of clearance and low estimates of distribution volumes (7,28-30), neither of which is reported here.
Hepatic blood flow, as estimated from indocyanine green clearance, was a significant covariate for propofol clearance in both normothermic and hypothermic volunteers, extending the findings of Lange et al. (31) who demonstrated a significant correlation between hepatic clearance of propofol and hepatic clearance of indocyanine green. Hepatic blood flow decreased -29% after the propofol infusion was started, a value somewhat greater than previously reported in animals 10% (32) and 17% (33)l and humans (14%) (31). Total hepatic blood flow is maintained when isoflurane (1.3%) and nitrous oxide (65%) are administered together (341, probably as a result of the specific hepatic arterial dilation produced by isoflurane (35). However, we gave considerably less isoflurane (0.6%), perhaps allowing the effects of nitrous oxide to dominate. Nitrous oxide produces a dose-dependent decrease in hepatic arterial, portal, and total hepatic blood flows (36). It is therefore likely that the effect of propofol on hepatic blood flow was potentiated by simultaneous administration of nitrous oxide. The administration of other drugs in this study is unlikely to have affected our results. Nitrous oxide and isoflurane potentially may alter the distribution or metabolism of propofol. However, as the end-tidal concentration of nitrous oxide and isoflurane was the same and constant in both groups, the difference in propofol blood concentration likely is due to other factors. Atracurium was not associated with a change in hepatic blood flow and does not decrease arterial blood pressure significantly (37). Similarly, the single bolus of thiopental presumably was nearly completely eliminated before hepatic blood flow estimation (38) .
The use of NONMEM and a data set comprising many samples from few individuals allowed us to concentrate our pharmacokinetic analysis on the effects of covariates such as hypothermia and hepatic blood flow on the structural component of the propofol model. This was particularly important in the case of hepatic blood flow, as any pharmacokinetic variable which changes over time in response to changes in a covariate is otherwise very difficult to analyze. Unfortunately, the small number of volunteers precluded obtaining accurate estimates of the population pharmacokinetics.
Hepatic blood flow did not differ in the hypothermic and normothermic groups. This is consistent with previous studies: splanchnic blood flow in dogs decreases only 10% at 35°C (391, and 15% at 32°C (10) . Maintenance of splanchnic blood flow during anesthetic-induced hypothermia results from redistribution of regional blood flow, with a shift from renal to splanchnic beds, despite decreases in cardiac output (40). The wide interindividual variation in our hepatic blood flow estimates impaired our ability to demonstrate small decreases in hepatic blood flow, if present.
We used the method of Soons et al. (19, 24) to estimate changes in hepatic blood flow, which allowed us to use indocyanine green clearance without necessitating hepatic venous cannulation or insertion of flow probes. Indocyanine green does not accumulate in blood during continuous infusion over 2.5 h (24), and therefore is suitable for multiple assessments of hepatic blood flow in one individual, provided steadystate conditions are achieved each time an assessment is made. We added a loading dose to the infusion to ensure that steady-state conditions were achieved before each measurement. Even after a 2.5-h infusion, indocyanine green is reported to have an elimination half-life of 4.0 ? 0.8 min (mean -+ SD) (24) indicating that 99% of individuals will have indocyanine green concentrations less than 0.2% of the level at the end of the previous infusion by the time indocyanine green clearance was estimated with each subsequent infusion. For these reasons, it is unlikely that accumulation of indocyanine green affected our hepatic blood flow estimations. After the example of Soons et al. (19) , we assumed a fixed hepatic extraction ratio of 0.7, and report only relative changes in hepatic blood flow.
Although indocyanine green clearance is widely used for hepatic blood flow estimation (24, 41, 42) , interindividual variation in indocyanine green hepatic extraction is high (50%-95%) (42). Indocyanine green clearance also is variable, both within (41) and among (19) individuals. Finally, propofol decreases the intrinsic clearance of indocyanine green, which may result in underestimation of decreases in hepatic blood flow (31,43). Despite these drawbacks, which may have resulted in discrepancies between our results and those of others (31-33), our results clearly indicate that propofol administration reduces hepatic blood flow.
The duration of atracurium action was prolonged -60% by 3°C of core hypothermia. These data are consistent with the observations that the infusion rate of atracurium required to maintain a constant level of blockade is reduced by 43% during cardiopulmonary bypass at 26°C (4~0, and by 35% at 30°C (45). Diefenbath et al. (46) demonstrated that atracurium duration of action was doubled during hypothermic (<32"C) compared with normothermic (>34"C) bypass, implying that temperature was the significant factor.
The mechanism by which hypothermia prolongs the effects of muscle relaxants remains controversial; it likely is multifactorial, the contribution of each factor being dependent on temperature (11, (44) (45) (46) (47) (48) . Potential pharmacokinetic mechanisms include a temperaturedependent change in elimination by Hofmann degradation or ester hydrolysis (13). Our result of an increase in the duration to Tl = 10% supports a pharmacokinetic mechanism, whereas no change in the duration Tl = 25%-75% suggests this is not the case. Decreased twitch tension due to hypothermia (16) is a potential cause of the apparent prolongation of atracurium action in this study, but this effect should be constant during the study period as control twitch tension was measured at the study temperature, and muscle temperature did not change significantly after atracurium administration. A more complete analysis of atracurium pharmacokinetics and dynamics during hypothermia is required to clarify this issue. Nevertheless, these data suggest that clinicians using atracurium in hypothermic patients should monitor both core temperature and neuromuscular function to avoid overdose. 1995;80:1007-14 HYPOTHERMIA, I'ROI'OEOL, AND ATRACURIUM
Other drugs used in this study potentially affected our results. Isoflurane is known to increase the duration of action of atracurium (49). However, isoflurane end-tidal concentrations were stable and identical in the two groups, for at least 5 h prior to atracurium administration.
The differences observed may therefore be ascribed to atracurium.
Propofol alone has no effect on neuromuscular function in clinical doses: only supraclinical doses potentiate blockade (50,511. We conclude that our results likely are not affected by varying propofol concentrations during atracurium administration, and by different concentrations in the normothermic and hypothermic groups. In conclusion, 3°C of core hypothermia was associated with higher propofol blood concentrations than normothermia.
The only pharmacokinetic variables having a significant association with hypothermia were the intercompartmental clearances, which were decreased in the presence of hypothermia. Hepatic blood flow was decreased during propofol administration, and this change was a significant predictor of propofol clearance, indicating that the effect of propofol on hepatic blood flow had implications for the clearance of propofol itself. The duration of action of atracurium was prolonged -60% by -3°C hypothermia. 
